Medpass Sarl is a Swiss consulting company specialized in business development, licensing, intelligence and regulatory services between China and Europe.
Xuming Shen (Managing Director), over 20 years experience in Europe in medical device and pharmaceutical industries, specialized in medical marketing, business development and licensing activities, serving multinational companies like Mylan, Medtronic.

Senior professionals

Pasquale Cetera is an executive with 35+ years of experience in the pharmaceutical business, with specific experience in the area of oncology and strategic portfolio management. Very diversified career with responsibilities in Marketing as well as R&D and Strategic Planning with the most important pharmaceutical companies, i.e. Pfizer, Novartis and Merck.

Elena Colajori (MD, Haematology) has over 30 years of experience in oncology drug development in an international pharmaceutical setting. After covering roles of Project Leader and Medical Product Leader for several compounds, she took over roles of increasing responsibilities including Medical Development Oncology Head for the R&D Italian Site in Pharmacia, Clinical Head for Oncology Europe in Pfizer, then Therapeutic Area Clinical Lead for Global Oncology in Pfizer and finally, VP Clinical Development Head Oncology Business Unit in Pfizer from 2008 to 2012. Her experience spans from early to late stage clinical development and includes successful worldwide registration of several oncology drugs.

Cristina Geroni has a long experience working in International Pharmaceutical R&D.  Cristina has extensive knowledge in experimental oncology (from basic research to entry in clinical evaluation) developing different classes of anticancer drugs. From 2004 to 2008 she was Associate Director Cellular Biology and Signal Transduction at NMS.  She is co-author of over 73 referred papers and is co-inventor of 57 patents.

Mark Griso Mark has thirty-five years experience in international Regulatory Affairs and CMC development and has   broad knowledge of legislation, guidelines and specific requirements for registration of NCEs, in many therapeutic areas, particularly oncology.  Mark has worked in strategic R&D development in defining optimum filing strategy and taking many compounds from ‘Proof of Concept’ through to registration. He has strong regulatory interactions with many Health Agencies. Until joining On-kos Mark was worldwide Head of Regulatory Affairs Oncology for Pfizer Inc.

Bruno Pagliara has worked in Pharmaceutical Marketing and BD held at international headquarter locations and has a successful track record in marketing,
 strategic planning, in and out licensing in the specialty pharmaceutical and in particular in the oncology area. Bruno was VP Corporate Development of Chiesi Pharma, a European multinationals company, during this period he finalized more than 15 major transactions in the US, Europe and Japan.
 Prior to Chiesi Bruno was VP Corporate BD Oncology for Pharmacia in London and VP of the Oncology Business Unit for Farmitalia Carlo Erba.

Gabriella Piscitelli (MD, PHD in Endocrinology) has over 20 years working in International Pharmaceutical Companies covering leadership positions in endocrine and oncology drugs development and medical affairs. Since 2004 she is consultant for clinical development in the oncology field including scientific and strategic advice and operational support for designing clinical development programs, design of clinical protocols, interpretation and reporting of results from clinical studies, preparation of clinical regulatory documentation, interaction with regulatory authorities for clinical aspects, due diligence for in-licensing candidates.
Prior to Clinical Development Consulting, Gabriella worked for Novartis as Medical Director Oncology Region Europe and Global Medical Brand Director for one of the company top priority compounds.  Before that she was: Senior Director Oncology at Pharmacia; International Project Leader Therapeutic Area Oncology at Pharmacia and Medical Responsible within Clinical Oncology for phase I-III clinical at Farmitalia. Gabriella has published 43 papers and 25 abstracts in the field of clinical oncology and endocrinology and is co-inventor of six patents.